ReviewMolecular biology reports2025
A review of recent advances in gene therapy, pharmacogenomics, and genetic polymorphisms in asthma.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several hereditary and environmental variables contribute to an individual's susceptibility to developing asthma. The pathophysiologic underpinnings of asthma are becoming better understood by ongoing genetic investigations. Most risk factors are differences in one or two base pairs or single-nucleotide polymorphisms (SNPs). Moreover, pharmacogenetics is a significant area of study in asthma genetics; this branch of the field examines the interplay between genes and environmental factors, with pharmacologic medication exposure serving as the environmental factor and phenotypic change as the result of interest. Asthma is an obvious candidate for gene therapy (GT) because of the disease's accessibility and the shortcomings of existing treatments. The functional effect of polymorphisms linked with asthma and their translation into disease-relevant pathways have been obfuscated since almost all of these variations are located in non-coding genomic areas. Repurposing current asthma medications and developing novel therapies may be possible with the help of genomics-guided identification of potential therapeutic targets for the condition. Further research using genomics data and tools to map and identify the relevant gene(s) and phenotype-specific SNPs is needed to understand better the processes involved in asthma's etiology and use pharmacogenomics to develop better medications for tailored treatment plans. This study uses fresh research to investigate the link between heredity and asthma. This research aimed to examine the impact of pharmacogenetic variables and gene therapies on the responsiveness to asthma therapy.
Indexed as
Identifiers
40439783What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.